Schrodinger, Inc. (SDGR) · Insider trading
What Schrodinger's directors, officers and largest holders bought and sold themselves, from the Form 4 each of them files with the SEC within two business days of a trade. Open-market purchases and sales first: those are the trades somebody chose to make at the market price.
Bought, 12 months
$0
0 insiders, 0 trades
Sold, 12 months
$2.30M
7 insiders, 100% under a plan
Net, 12 months
−$2.30M
bought less sold
Latest filing
2026-09-21
filings read to 2026-10-19
Who traded, two years
| Insider | Bought | Sold | Trades | Last trade | Holds after |
|---|---|---|---|---|---|
| Akinsanya KarenSee Remarks | – | $1.39M | 7 | 2026-09-17 | 91,555 |
| Farid RamyDirector, President & CEO | – | $1.17M | 4 | 2026-04-17 | 330,824 |
| Tran YvonneEVP, CLO & CPO | – | $154,305 | 4 | 2026-03-05 | 52,683 |
| Porges Geoffrey CraigEVP & CFO | – | $119,484 | 1 | 2025-03-03 | 27,544 |
| Abel Robert LorneSee Remarks | – | $65,108 | 3 | 2026-03-04 | 55,897 |
| Herman JennyCAO | – | $63,180 | 5 | 2026-03-06 | 34,804 |
| Lorton Kenneth PatrickEVP, CTO & COO, Software | – | $52,528 | 3 | 2026-03-05 | 89,241 |
| Jain RachitEVP & CFO | – | $45,451 | 3 | 2026-07-16 | 50,877 |
| Dugan MargaretChief Medical Officer | – | $29,393 | 1 | 2025-10-16 | 24,574 |
Open-market purchases and sales
Newest first. “Plan” marks a trade made under a 10b5-1 plan set up in advance.
| Date | Insider | Trade | Shares | Price | Value | Holds after | Filing |
|---|---|---|---|---|---|---|---|
| 2026-09-17 | Akinsanya KarenSee Remarks | Saleplan | 10,000 | 28.00 | $280,000 | 91,555 | Form 4 |
| 2026-09-17 | Akinsanya KarenSee Remarks | Saleplan | 21,599 | 30.00 | $647,970 | 69,956 | Form 4 |
| 2026-07-16 | Jain RachitEVP & CFO | Saleplan | 875 | 15.60 | $13,650 | 50,877 | Form 4 |
| 2026-04-17 | Farid RamyDirector, President & CEO | Saleplan | 43,000 | 12.21 | $525,030 | 330,824 | Form 4 |
| 2026-04-16 | Farid RamyDirector, President & CEO | Saleplan | 43,000 | 12.33 | $530,190 | 330,824 | Form 4 |
| 2026-04-16 | Jain RachitEVP & CFO | Saleplan | 844 | 12.75 | $10,761 | 51,752 | Form 4 |
| 2026-03-06 | Herman JennyCAO | Saleplan | 608 | 12.84 | $7,807 | 34,804 | Form 4 |
| 2026-03-05 | Akinsanya KarenSee Remarks | Saleplan | 1,366 | 12.90 | $17,621 | 69,956 | Form 4 |
| 2026-03-05 | Farid RamyDirector, President & CEO | Saleplan | 3,661 | 12.91 | $47,264 | 330,824 | Form 4 |
| 2026-03-05 | Lorton Kenneth PatrickEVP, CTO & COO, Software | Saleplan | 1,222 | 12.90 | $15,764 | 89,241 | Form 4 |
| 2026-03-05 | Tran YvonneEVP, CLO & CPO | Saleplan | 1,094 | 12.90 | $14,113 | 52,683 | Form 4 |
| 2026-03-05 | Herman JennyCAO | Saleplan | 775 | 12.85 | $9,959 | 35,412 | Form 4 |
| 2026-03-05 | Jain RachitEVP & CFO | Saleplan | 1,631 | 12.90 | $21,040 | 52,596 | Form 4 |
| 2026-03-04 | Abel Robert LorneSee Remarks | Saleplan | 1,300 | 12.81 | $16,653 | 55,897 | Form 4 |
| 2026-03-02 | Akinsanya KarenSee Remarks | Saleplan | 2,206 | 11.99 | $26,450 | 71,322 | Form 4 |
| 2026-03-02 | Farid RamyDirector, President & CEO | Saleplan | 5,560 | 11.90 | $66,164 | 334,485 | Form 4 |
| 2026-02-10 | Lorton Kenneth PatrickEVP, CTO & COO, Software | Saleplan | 925 | 13.73 | $12,700 | 52,651 | Form 4 |
| 2026-02-10 | Tran YvonneEVP, CLO & CPO | Saleplan | 776 | 13.80 | $10,709 | 22,859 | Form 4 |
| 2026-02-10 | Herman JennyCAO | Saleplan | 752 | 13.79 | $10,370 | 26,597 | Form 4 |
| 2026-02-09 | Abel Robert LorneSee Remarks | Saleplan | 1,230 | 13.51 | $16,617 | 19,385 | Form 4 |
| 2025-10-16 | Dugan MargaretChief Medical Officer | Saleplan | 1,395 | 21.07 | $29,393 | 24,574 | Form 4 |
| 2025-04-14 | Akinsanya KarenPresident of R&D, Therapeutics | Saleplan | 8,378 | 25.11 | $210,372 | 23,970 | Form 4 |
| 2025-04-14 | Akinsanya KarenPresident of R&D, Therapeutics | Saleplan | 5,000 | 25.11 | $125,550 | 18,970 | Form 4 |
| 2025-04-14 | Akinsanya KarenPresident of R&D, Therapeutics | Saleplan | 3,345 | 25.00 | $83,625 | 15,625 | Form 4 |
| 2025-03-06 | Herman JennySVP & Controller | Saleplan | 666 | 21.11 | $14,059 | 27,349 | Form 4 |
| 2025-03-03 | Porges Geoffrey CraigEVP & CFO | Sale | 5,491 | 21.76 | $119,484 | 27,544 | Form 4 |
| 2025-02-18 | Tran YvonneEVP, CLO & CPO | Saleplan | 3,902 | 28.00 | $109,256 | 11,135 | Form 4 |
| 2025-02-11 | Tran YvonneEVP, CLO & CPO | Saleplan | 828 | 24.43 | $20,228 | 11,135 | Form 4 |
| 2025-02-11 | Herman JennySVP & Controller | Saleplan | 859 | 24.43 | $20,985 | 18,215 | Form 4 |
| 2025-02-11 | Lorton Kenneth PatrickEVP, CTO & COO, Software | Saleplan | 985 | 24.43 | $24,064 | 41,076 | Form 4 |
| 2025-02-10 | Abel Robert LorneSee Remarks | Saleplan | 1,225 | 25.99 | $31,838 | 8,115 | Form 4 |
Grants, exercises and other transactions
Pay, tax and paperwork rather than a choice to trade at the market price. Two years.
45 × grant or award8 × option exercise2 × gift
Show them
| Date | Insider | What | Shares | Price | Holds after | Filing |
|---|---|---|---|---|---|---|
| 2026-09-17 | Akinsanya KarenSee Remarks | Option exercise M | +31,599 | 4.34 | 101,555 | Form 4 |
| 2026-06-26 | Friesner RichardDirector | Gift G | −679,373 | – | 0 | Form 4 |
| 2026-06-26 | Friesner RichardDirector | Gift G | +679,373 | – | 679,373 | Form 4 |
| 2026-06-22 | Ginsberg Gary LDirector | Grant or award A | +8,141 | – | 25,388 | Form 4 |
| 2026-06-22 | Oberoi ArunDirector | Grant or award A | +8,141 | – | 25,388 | Form 4 |
| 2026-06-22 | van Kralingen Bridget ADirector | Grant or award A | +8,141 | – | 19,640 | Form 4 |
| 2026-06-22 | Lynton MichaelDirector | Grant or award A | +8,141 | – | 25,388 | Form 4 |
| 2026-06-22 | Chodakewitz JeffreyDirector | Grant or award A | +8,141 | – | 25,388 | Form 4 |
| 2026-06-22 | Sender GaryDirector | Grant or award A | +8,141 | – | 25,388 | Form 4 |
| 2026-06-22 | Thornberry NancyDirector | Grant or award A | +8,141 | – | 25,388 | Form 4 |
| 2026-06-22 | Kapeller-Libermann RosanaDirector | Grant or award A | +8,141 | – | 25,388 | Form 4 |
| 2026-06-22 | Friesner RichardDirector | Grant or award A | +8,141 | – | 690,365 | Form 4 |
| 2026-04-17 | Farid RamyDirector, President & CEO | Option exercise M | +43,000 | 3.07 | 373,824 | Form 4 |
| 2026-04-17 | Farid RamyDirector, President & CEO | Option exercise M | +74,527 | 3.07 | 405,351 | Form 4 |
| 2026-04-16 | Farid RamyDirector, President & CEO | Option exercise M | +43,000 | 3.07 | 373,824 | Form 4 |
| 2026-03-02 | Akinsanya KarenSee Remarks | Grant or award A | +24,250 | – | 39,875 | Form 4 |
| 2026-03-02 | Akinsanya KarenSee Remarks | Grant or award A | +6,077 | – | 45,952 | Form 4 |
| 2026-03-02 | Akinsanya KarenSee Remarks | Grant or award A | +27,576 | – | 73,528 | Form 4 |
| 2026-03-02 | Farid RamyDirector, President & CEO | Grant or award A | +56,250 | – | 278,182 | Form 4 |
| 2026-03-02 | Farid RamyDirector, President & CEO | Grant or award A | +13,604 | – | 291,786 | Form 4 |
| 2026-03-02 | Farid RamyDirector, President & CEO | Grant or award A | +48,259 | – | 340,045 | Form 4 |
| 2026-03-02 | Lorton Kenneth PatrickEVP, CTO & COO, Software | Grant or award A | +17,130 | – | 69,781 | Form 4 |
| 2026-03-02 | Lorton Kenneth PatrickEVP, CTO & COO, Software | Grant or award A | +20,682 | – | 90,463 | Form 4 |
| 2026-03-02 | Tran YvonneEVP, CLO & CPO | Grant or award A | +17,130 | – | 39,989 | Form 4 |
| 2026-03-02 | Tran YvonneEVP, CLO & CPO | Grant or award A | +13,788 | – | 53,777 | Form 4 |
| 2026-03-02 | Herman JennyCAO | Grant or award A | +9,590 | – | 36,187 | Form 4 |
| 2026-03-02 | Abel Robert LorneSee Remarks | Grant or award A | +17,130 | – | 36,515 | Form 4 |
| 2026-03-02 | Abel Robert LorneSee Remarks | Grant or award A | +20,682 | – | 57,197 | Form 4 |
| 2026-03-02 | Friesner RichardDirector | Option exercise M | +160,527 | 3.07 | 682,224 | Form 4 |
| 2026-03-02 | Aklian Mannix VartanSee Remarks | Grant or award A | +17,130 | – | 31,193 | Form 4 |
| 2026-03-02 | Jain RachitEVP & CFO | Grant or award A | +17,130 | – | 54,227 | Form 4 |
| 2025-06-18 | Friesner RichardDirector | Grant or award A | +5,997 | – | 521,697 | Form 4 |
| 2025-06-18 | Oberoi ArunDirector | Grant or award A | +5,997 | – | 17,247 | Form 4 |
| 2025-06-18 | Ginsberg Gary LDirector | Grant or award A | +5,997 | – | 17,247 | Form 4 |
| 2025-06-18 | Kapeller-Libermann RosanaDirector | Grant or award A | +5,997 | – | 17,247 | Form 4 |
| 2025-06-18 | Thornberry NancyDirector | Grant or award A | +5,997 | – | 17,247 | Form 4 |
| 2025-06-18 | van Kralingen Bridget ADirector | Grant or award A | +1,499 | – | 11,499 | Form 4 |
| 2025-06-18 | Lynton MichaelDirector | Grant or award A | +5,997 | – | 17,247 | Form 4 |
| 2025-06-18 | Sender GaryDirector | Grant or award A | +5,997 | – | 17,247 | Form 4 |
| 2025-06-18 | Chodakewitz JeffreyDirector | Grant or award A | +5,997 | – | 17,247 | Form 4 |
| 2025-05-29 | Aklian Mannix VartanSee Remarks | Grant or award A | +14,063 | – | 14,063 | Form 4 |
| 2025-05-21 | Jain RachitEVP & CFO | Grant or award A | +9,375 | – | 37,097 | Form 4 |
| 2025-04-14 | Akinsanya KarenPresident of R&D, Therapeutics | Option exercise M | +13,378 | 3.22 | 29,003 | Form 4 |
| 2025-04-14 | Akinsanya KarenPresident of R&D, Therapeutics | Option exercise M | +3,345 | 2.92 | 32,348 | Form 4 |
| 2025-03-07 | van Kralingen Bridget ADirector | Grant or award A | +10,000 | – | 10,000 | Form 4 |
| 2025-03-03 | Abel Robert LorneSee Remarks | Grant or award A | +12,500 | – | 20,615 | Form 4 |
| 2025-03-03 | Tran YvonneEVP, CLO & CPO | Grant or award A | +12,500 | – | 23,635 | Form 4 |
| 2025-03-03 | Lorton Kenneth PatrickEVP, CTO & COO, Software | Grant or award A | +12,500 | – | 53,576 | Form 4 |
| 2025-03-03 | Herman JennySVP & Controller | Grant or award A | +9,800 | – | 28,015 | Form 4 |
| 2025-03-03 | Dugan MargaretChief Medical Officer | Grant or award A | +12,500 | – | 25,969 | Form 4 |
| 2025-03-03 | Farid RamyDirector, President & CEO | Grant or award A | +37,500 | – | 221,932 | Form 4 |
| 2025-03-03 | Akinsanya KarenPresident of R&D, Therapeutics | Grant or award A | +15,625 | – | 15,625 | Form 4 |
| 2025-03-03 | Porges Geoffrey CraigEVP & CFO | Grant or award A | +12,500 | – | 18,185 | Form 4 |
| 2025-03-03 | Porges Geoffrey CraigEVP & CFO | Grant or award A | +14,850 | – | 33,035 | Form 4 |
| 2025-02-18 | Tran YvonneEVP, CLO & CPO | Option exercise M | +3,902 | 4.34 | 15,037 | Form 4 |
How to read it
- Buy, sale
- Code P and S on the form: shares bought or sold in the market, at the market price. The other codes are mostly pay (a grant, an option exercised) or tax (shares the company withheld), and say little about what the insider thinks of the price.
- Plan
- A sale or purchase under a Rule 10b5-1 plan, set up in advance and running on its own schedule. Since April 2023 the form has a box for it. Much executive selling is planned and says more about diversifying than about the company.
- Holds after
- The shares the insider still held after the trade, in the form the trade was in (directly, or indirectly through a trust or a fund).
- Value
- Shares times the price the form reports, which is often an average over several fills on the day.
Read from the SEC's own quarterly data sets of Forms 3, 4 and 5, and from each day's filings since the last one. A correcting amendment replaces the lines it restates. Every row links to its filing. None of this is advice: insiders sell for many reasons, and buy for fewer.